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Abstract
Background: Acquisition of a blood supply is fundamental for extensive tumor growth. We recently described vascular
heterogeneity in tumours derived from cell clones of a human mesenchymal stem cell (hMSC) strain (hMSC-TERT20)
immortalized by retroviral vector mediated human telomerase (hTERT) gene expression. Histological analysis showed that
cells of the most vascularized tumorigenic clone, -BD11 had a pericyte-like alpha smooth muscle actin (ASMA+) and CD146+
positive phenotype. Upon serum withdrawal in culture, -BD11 cells formed cord-like structures mimicking capillary
morphogenesis. In contrast, cells of the poorly tumorigenic clone, -BC8 did not stain for ASMA, tumours were less
vascularized and serum withdrawal in culture led to cell death. By exploring the heterogeneity in hMSC-TERT20 clones we
aimed to understand molecular mechanisms by which mesenchymal stem cells may promote neovascularization.
Methodology/Principal Findings: Quantitative qRT-PCR analysis revealed similar mRNA levels for genes encoding the
angiogenic cytokines VEGF and Angiopoietin-1 in both clones. However, clone-BD11 produced a denser extracellular matrix
that supported stable ex vivo capillary morphogenesis of human endothelial cells and promoted in vivo neovascularization.
Proteomic characterization of the -BD11 decellularized matrix identified 50 extracellular angiogenic proteins, including
galectin-1. siRNA knock down of galectin-1 expression abrogated the ex vivo interaction between decellularized -BD11
matrix and endothelial cells. More stable shRNA knock down of galectin-1 expression did not prevent -BD11 tumorigenesis,
but greatly reduced endothelial migration into -BD11 cell xenografts.
Conclusions: Decellularized hMSC matrix had significant angiogenic potential with at least 50 angiogenic cell surface and
extracellular proteins, implicated in attracting endothelial cells, their adhesion and activation to form tubular structures.
hMSC -BD11 surface galectin-1 expression was required to bring about matrix-endothelial interactions and for xenografted
hMSC -BD11 cells to optimally recruit host vasculature.
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Introduction
Bone marrow derived hMSC may have a supportive role in
tumorigenesis [1], even possibly an ontogenic role in Ewing’s
sarcomas [2] where angiogenesis and vasculogenesis are promi-
nent. To improve upon existing outcomes (long term survival
typically ,50%), alternative therapeutic strategies include disrup-
tion of how these sarcomas obtain and maintain a blood supply
[3]. Since tumorigenic cells can acquire a blood supply via distinct
processes, detailed understanding of the specific molecular
mechanisms involved is required for appropriate therapeutic
strategies. Angiogenesis (new blood vessels from pre-existing
vessels), or tumour vasculogenesis (recruitment of bone marrow
endothelial progenitor cells to form de novo vessels) are influenced
by vascular endothelial growth factor (VEGF) [4]. In contrast,
VEGF apparently contributed little to a process termed vasculo-
genic mimicry, when Ewing sarcoma cells themselves contributed
to the vascular network [5].
In addition to cellular secretion of angiogenic factors such as
VEGF, the production of extracellular matrix contributes to
vascularization by a wide range of dynamic mechanisms. Cell
signalling is mediated via adhesion receptors such as integrins,
sequestered growth factors [6] and mechanical characteristics of the
matrix, which combine to influence endothelial cell differentiation,
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angiogenesis probablyinvolve differentformsofextracellularmatrix
(ECM) and endothelial-ECM interactions and there is a need for a
better understanding of the potential players and their roles [8].
Bone marrow derived hMSC can function as perivascular cells,
stabilizing engineered vessels when combined with endothelial
cells [9]. Indeed, a consistent perivascular location in a broad
range of tissues, has led to the hypothesis that hMSC may have a
perivascular origin [10], defining an intimate association with
vasculature. We recently described clone-specific heterogeneity in
the vascularization of tumours derived from hMSC-TERT20 cells
[11],[12]. This tumorigenic model [13] evolved spontaneously
from long-term passage of telomerized hMSC [14] that had
hitherto retained the phenotype of primary mesenchymal stem
cells including multipotent differentiation potential [15]. Thus
hMSC-TERT20 clones provided a versatile model for tumour
vascularization within the context of a perivascular cell type.
Molecular mechanisms governing how the most angiogenic clone
recruits vasculature may be broadly relevant for both anti-
angiogenic tumor therapy and current investigations regarding the
application of mesenchymal stem cells for clinical treatment of
ischemia [16]. Here, we show that upon serum starvation, the
most angiogenic tumor clone -BD11 produced an extracellular
matrix that supported autonomous cord-like cellular reorganisa-
tion, resembling the capillary morphogenesis of endothelial cells
cultured on Matrigel
TM. Decellularized -BD11 cell matrix could
guide cord-like cellular organisation of seeded endothelial cells and
moreover, sufficed to promote neovascularization in an in vivo
Matrigel
TM encapsulated sponge assay. Preliminary characterisa-
tion via mass spectrometry of metabolically labelled decellularized
matrix identified 50 cell surface proteins known to have a role in
angiogenesis. Among them, galectin-1 was expressed in serum-
deprived cultures of -BD11 cells and played a key role in
decellularized hMSC matrix-endothelial interactions and neovas-
cularization in vivo.
Results
Potently tumorigenic -BD11 cells survived serum
starvation with spontaneous cord morphogenesis
The previously described clonal cell lines: hMSC-TERT20-
BC8 (-BC8) and -hMSC-TERT20-BD11 (-BD11), showed
different tumorigenic potential [11] correlated to the extent of
tumour-related vasculature [12]. As seen for primary bone
marrow derived hMSC (Figure 1A), their vasculogenic phenotype
included cord formation on Matrigel (Figure 1B,1 C). Removing
serum from confluent -BC8 (Figure 1D) or -BD11 (Figure 1G)
‘‘cobblestone’’ monolayers, promptly led to cell proliferation and
migration, both clones yielding circular lacunae approximately
40 mm in diameter within 6 hours. Yet within 72 hours, growth of
-BC8 cells stopped (Figure 1J) and these cells died (Figure 1F)
whereas -BD11 cells proliferated forming cell cords (Figure 1I).
Time-lapse photography of -BD11 cells revealed three main
phases to branching cell cord network formation (Supplementary
Movie S1). Within 24 hours of serum starvation there was
extensive mitotic activity. During the 24–48 hour period, cells
condensed towards each other, retracting the borders of the
growing lacunae. Subsequently, in a consolidation phase, the cords
of cells maintained their honeycomb-like network pattern
distribution with less cell migration and cell division. The -BD11
viability persisted in replenished serum-free medium for at least
three weeks. Occasionally, a sprouting lamellipodium ending with
a focal contact point (FCP), projected into the acellular space.
Whilst the lacunae circumference increased, the non-dividing cell
body retracted towards neighbouring cells, extending the length of
the lamellipodium in the process (Fig. 1K). Subsequently, a cell
could migrate into the lacuna towards its lamellopodial focal
contact point and continue its migration. Cell cord morphogenesis
was reversible. Upon addition of serum-containing medium the
cells re-established a confluent monolayer.
Both serum-starved clones expressed Ang-1, Ang-2, Tie-1, Tie-
2, CD31, CD105 and VEGFa mRNA, whereas -BD11 cells also
expressed low levels of VEGFR-2 mRNA, increasingly detected
during the serum starvation time course (Figure 1L). Reflecting low
expression, VEGFR-2 or CD31 protein was not readily detected
by FACS analysis of -BC8 or -BD11 cells cultured in ECBM-MV2
medium (data not shown). Notably, control TIME endothelial cells
did not express Ang-1 but had greater PCR band intensity for
Ang-2, Tie-1, CD31 and VEGFR-2.
The cord morphogenesis observed in serum depleted -BD11
and -BC8 cells was sometimes observed in subregions of primary
hMSC cultures (Figure 1M,N,O), thus this starvation phenotype
was expressed by a subset of primary cells.
-BD11 cells were more angiogenic than clone -BC8 cells
The matrigel encapsulated sponge angiogenesis (MESA) assay
tested whether spontaneous ex vivo capillary morphogenesis
correlated with neovascularization. The one-week angiogenic
response was greater for -BD11 than -BC8 cells. Clone -BD11
MESA assays had numerous vessels containing a FITC positive
lumen (Figure 2A), confirming functional conduit vessels, but this
was rare in -BC8 assays (Figure 2B). Nonetheless in both cases,
hMSC cells within the sponge scaffold were CD99+, a marker for
human cells (Figure 2C,2 D). The staining pattern for endothelial
cell biomarkers was positive for murine-specific CD34 (Figure 2E)
and negative for human-specific CD31 (Figure 2F), thus
endothelial cells were host derived. Most vascular mural cells
strongly positive for a-smooth muscle actin did not co-stain with
human specific biomarker TRA-1-85 (Figure 2G–2J). However,
TRA-1-85+ cells were found directly adjacent to endothelial cells,
suggesting a possibly mixed murine and human cell contribution
to pericyte cells in early stages of vessel formation.
Decellularized -BD11 matrix promoted human
endothelial cell tubular morphogenesis ex vivo
Since expression of angiogenic factors VEGF-A and Angio-
poietin-1 were equivalent and unlikely to explain differences in the
revascularization potential of the clone-derived tumors, we
explored extracellular matrix (ECM) expression. Our results
agreed with studies that emphasized a role for hMSC ECM in
maintaining vasculature structure [17]. Despite similar cell
morphology under phase contrast microscopy, protein gel
electrophoresis of equivalent amounts of decellularized matrix
from confluent -BC8 versus -BD11 monolayer cultures differed
markedly, with a much more complex protein band pattern for
clone -BD11 (Fig. 3A).
Comparing the endothelial support of decellularized matrix
from serum-starved clones, TIME endothelial cells association
with matrix from -BC8 cells only poorly, lacking close alignment
(Figure 3B,3 C). In contrast, TIME cells closely populated the
decellularized matrix from -BD11 cells forming an aligned cord-
like network pattern (Figure 3D, 3E). Consistent with previous
observations [18] the -BD11 clone could form long cellular cords
elevated above the surface of the monolayer, surrounded by
culture medium. Suspended cords of matrix, retained after gentle
decellularization, were templates for rapid adhesion and alignment
of freshly seeded endothelial cells (Figure 3F). Subsequently, a
stable endothelial cell tubular structure formed around the -BD11
hMSC Extracellular Matrix Proteins and Vasculature
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the matrix scaffold (Figures 3H–3J).
Decellularized -BD11 matrix promoted endothelial cell
migration in vivo
In the sensitive directional MESA assay (Figure 4A), very few
CD34+ murine endothelial cells migrated through the MatrigelH
plug towards the control sponge pre-incubated with culture
medium alone (Figure 4B). For sponges loaded with -BC8 cells,
few murine CD34
+ endothelial cells reached the sponge periphery
(Figure 4C), but loaded with -BD11 cells many more did so
(Figure 4D); Chalkley counts indicated a significant difference
(Fig. 4E), p=0.02 (Kruskal-Wallis). Given decellularized matrix-
endothelial interactions ex vivo, the MESA assay was repeated using
decellularized -BD11 matrix. In contrast to control MESA assays
(Fig. 4F) sponges loaded with decellularized matrix contained
closely aligned migratory endothelial cells attached to the blue
stained matrix (Figure 4G). Within the same matrigel plug, regions
without collagen fibril staining had very few endothelial cells
(Figure 4H), whereas matrix-dense regions had numerous CD34
+
murine endothelial cells (Figure 4I). The resulting mean Chalkley
count for decellularized matrix in the MESA assay (9.361.53) was
significantly greater than the control sponge (2.360.76), ap-
proaching the score for whole -BD11 cells (10.2761.2). Decel-
lularized matrix from primary hMSC led to Chalkley counts
equivalent to clone -BC8 rather than -BD11 (Figure 4E),
highlighting the latter clone had distinctive extracellular matrix
with greater angiogenic potential than untransformed hMSC.
SILAC Mass spectrometry of proteins in decellularized
matrix from -BD11 cells
Since decellularized -BD11 matrix efficiently evoked excellent
endothelial tubular structures ex vivo and promoted neovascular-
ization, we aimed to identify inherent surface proteins that might
account for endothelial attachment, activation and in vivo
chemoattraction. Mass spectrometry peptide identification
achieved high levels of confidence, with individual peptide ion
identity having a false-positive rate estimation of ,0.05. Favouring
a protocol for endothelial recellularization [19], rather than for
absolute matrix purity it was expected that we would co-purify
Figure 1. Cord formation of primary hMSC and hMSC-TERT clones. Cord morphogenesis with cell sprouting in A: Primary hMSC, B: -BC8 and
C: -BD11 induced by culture on MatrigelH overnight. D,E,F: Phase contrast photomicrographs of -BC8 and G,H,I: -BD11 cells during serum starvation.
D,G: confluent cells before serum starvation for E,H: 2 days and F,I: 7 days. J, Growth curves for -BC8 (%) and -BD11 (N) in serum free medium,
*p,0.05. K: -BD11 cells after 72 hours in serum free medium, showing early cell sprouts (S) and a lamellipodium terminating in a focal contact point
(FCP) within the lacuna. L: RT-PCR analysis of cDNA obtained from serum-starved hMSC-TERT20 clones (time without serum indicated in hours).
M,N,O: Independent examples of plastic adherent primary hMSCs spontaneously forming cords when depleted of growth factors for 2 weeks.
doi:10.1371/journal.pone.0021888.g001
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cell sprouting, it was noteworthy that intracellular proteins
included Protein kinase Cd, IQmotif GTPase (IQGAP1), Ras
associated protein (Rap1b), Chloride Intracellular Channel 4
(CLIC4), Cofilin-1, Fascin, Myosin 9, Profilin-1, Talin-1 and
Vimentin. More relevant for interaction with endothelial cells, we
identified SILAC-labelled peptides for 50 cell surface/extracellular
proteins with angiogenic function (Table 1).
Endothelial cell attachment to decellularized matrix ex
vivo required -BD11 Galectin-1 expression
Galectin-1 was abundantly expressed in primary bone marrow
derived hMSC [20] and was chosen from the list of SILAC-
labelled proteins as a target for functional analysis to test our
cellular model. In comparison to the Galectin-1 levels of the initial
-BD11 population in 10% FBS, serum starved -BD11 cells showed
a <40% increase in Galectin-1 mRNA (Figure 5A) and protein
expression (Figure 5B). The levels of Galectin-1 protein expression
in -BD11 cell Western blots resembled that of TIME endothelial
cells (Figure 5C). The siRNA mediated knock down of Galectin-1
expression was confirmed at the mRNA (Figure 5A) and protein
(Figure 5C) level. In -BD11 cells grown in medium supplemented
with 10% FBS, siRNA knock down of Galectin-1 had no marked
effect on cell morphology (Figure 5D,5 E) or growth rate
(Figure 5H). However, in serum-starved conditions, LGALS1
siRNA treated BD11 cells formed a less uniform network pattern
(Figure 5G) and at 72 hours cell number was modestly reduced by
<35% compared to BD11 cells transfected with sham control
siRNA (Figure 5H). TIME human endothelial cells seeded on the
decellularized matrix prepared from -BD11 cells transfected with
sham siControl RNA and serum-starved for 72 hours (Figure 5I),
attached preferentially to the underlying matrix rather than
culture plastic; forming a corresponding pattern of aligned
endothelial cells within 30 minutes (Figure 5K). In contrast, when
using decellularized matrix prepared from siGALS1 knock down
-BD11 cells (Figure 5J), the endothelial cells showed no
preferential attachment to the matrix (Figure 5L). We tested
whether attachment to the underlying matrix network significantly
influenced the pattern of endothelial cell distribution, by
determining the Ripley’s K function for the seeded endothelial
cells. ImageJ software determined spatial point coordinate data for
endothelial cells seeded on matrix from -BD11 cells treated with
siControl (Figure 5M) or siGALSN1 (Figure 5N). The observed
point patterns of endothelial cells on siControl -BD11 decellular-
ized matrix were consistently above a random expectation
(Figure 5O) reflecting non-random covariate cell clustering on
the matrix. Pattern intensity for endothelial cells seeded on
siGALSN1 decellularized matrix led to curves matching an
expected random Poisson pattern distribution (Figure 5P), reflect-
ing that endothelial cells did not selectively attach to the
underlying decellularized matrix. These differences in attachment
to decellularized matrix were not only transient; different cell
distribution patterns persisted for at least ten days in culture
(Figure 5Q,5 R).
Endothelial cell association with -BD11 cells in vivo
required matrix Galectin-1 expression
To more stringently test a role for Galectin-1 in -BD11-
endothelial interaction we used shRNA vector technology to
obtain pooled colonies of -BD11 cells with more stable knock
down of Galectin-1 (Figure 6A). Tumours (n=4) arising from
-BD11 pooled cells transfected with shGALSN1 vector reached an
average volume of 2.52 cm
3 after 2 weeks, in close agreement with
previous tumorigenicity studies [11]. Nonetheless, immunohisto-
chemistry showed that unlike the multi-compartment intracellular
and extracellular galectin-1 expression seen in shControl -BD11
tumours (Figure 6B), for -BD11 tumor cells transfected with the
Figure 2. Matrigel encapsulated sponge angiogenesis assay
(MESA). Consecutive 4 mm histological sections from matrigel plugs
isolated after 7 days in vivo. A,B: Anti-FITC antibody visualized by brown
chromogen diaminobenzidine, detected the blood pooling agent FITC-
Dextran, indicating anastomosis with host circulation. A: Sponge region
with -BD11 cells. B: Sponge region with -BC8 cells. C,D: Human specific
anti-CD99 was used to confirm presence of C: -BD11 and D: -BC8 cells. E:
Murine specific anti-CD34 stain of the sponge region with -BD11 cells. F:
A parallel section stained with human specific anti-CD31. G–J: Laser
scanning confocal microscopy of 4 mm histological sections of plugs
seeded with -BD11 cells 636magnification. G: a-smooth muscle actin
stain visualized with goat anti mouse IgG2b Alexa 488 (green); H: TRA-1-
85 stain visualized with goat anti mouse IgG1 Alexa 555 (red); I: DAPI
stain of nuclei (blue); J: G–I overlay. N.B. red blood cells have red and
green spectrum autofluorescence and appear orange. No cells double-
stained for a-smooth muscle actin and TRA-1-85. Scale bar, A–F:
100 mm; G–J:1 0mm.
doi:10.1371/journal.pone.0021888.g002
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nucleus (Figure 6C). Though observed in the tumour periphery,
serial sections showed remarkably few CD34+ murine endothelial
cells amongst the CD99+ tumor cells, Chalkley counts typically
,260.4 (Figure 6D). In one case, a dense cluster of CD34+ cells
was found closely adjacent to the main tumour mass (Figure 6E,
6F) and this region colocalised with CD99+ human cells
(Figure 6G). Immunohistochemical analysis of Galectin-1
(Figure 6H) revealed close association of CD34+ murine
endothelial cells with human cells only where Galectin-1
expression was also prominent in the extracellular matrix
(Figure 6I, 6J).
Discussion
The heterogenous tumorigenic phenotypes among hMSC-
TERT20 clones advantageously involved a cell type capable of
contributing to vasculature as a pericyte. Given a rate-limiting
influence of angiogenesis on tumorigenicity, we conjectured that
clones with fast-growing tumours would express an optimal
phenoype for acquisition of a blood supply. In agreement, the
-BD11 clone expressed relatively high levels of a-smooth muscle
actin and induced greater vascularity in vivo. Moreover, ex vivo
survival of serum starvation included autonomous formation of
stable cell cord networks, attributable to production of a more
complex ECM [21]. Decellularized matrix prepared from serum-
starved -BD11 cells induced endothelial cell cord formation ex vivo
and angiogenesis in vivo. We used cell-labelled SILAC proteomics
to identify 50 angiogenic proteins in the decellularized matrix with
roles in endothelial chemoattraction, attachment and activation
for sprouting and tube formation. Targeting galectin-1 revealed
crucial roles in mediating both ex vivo serum-starved -BD11 matrix-
human endothelial cell interactions and in vivo associations
between these xenografted human hMSC and murine endothelial
cells.
Our model may introduce biases specific for the angiogenic
potency of telomerized hMSC within the context of tumour
formation. However, global gene expression studies noted close
overall similarity between disparate angiogenic situations and
highlighted a role for ECM molecules [22]. Subregions of primary
hMSC cultures sometimes showed autonomous cord morphogen-
esis in growth factor depleted conditions, supporting relevance for
non-transformed bone marrow stromal cells. Spontaneous capil-
lary morphogenesis on culture plastic under serum-free conditions,
Figure 3. Analysis of hMSC-TERT-BC8 and -BD11 extracellular matrix (ECM). Sodium dodecyl sulfate polyacrylamide gel electrophoresis of
equivalent total protein extracts of decellularized cells. A: Silver stained -BC8 proteins (left lane) and -BD11 proteins (right lane). Phase contrast
photomicrographs of TIME endothelial cells seeded on decellularized matrix derived from B,C: -BC8 and D,E -BD11 clones on plastic dishes after B,D:1
day or C,E: 10 days after seeding. Tubular cord formation by TIME cells when seeded on decellularized -BD11 matrix. F: Phase contrast
photomicrographs of TIME cells aligned along detached free-floating cords of decellularized matrix within 2 hours of seeding. G: At 21 days, stable
endothelial cord structures were maintained. H–J: 3D reconstructed images of TIME cells from a 21 day old cord structure stained with a FITC labeled
Ulex Europaeus agglutinin lectin I (green) and propidium iodine counterstained nuclei (red) obtained with confocal microscopy. H: A longitudinal
view of the tubule at 636magnification. Red lines indicate region corresponding to XZ sections in adjacent figures. I,J: XZ-section stacks were used
for cross section 3D-reconstruction showing TIME cell tube-like organization. Scale bar, B–E: 100 mm; H–J:1 0mm.
doi:10.1371/journal.pone.0021888.g003
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line, F-2C [23]. The -BD11 cells provide the first example of a
human cell line displaying such a phenotype. A key advantage is
that ex vivo cord formation studies no longer required Matrigel
TM
(a complex mixture of murine laminin, type IV collagen and
fibronectin extracellular matrix components derived from murine
Engelbroth-Holm-Swarm (EHS) sarcomas) as an inductive
substrate. Its composition poorly represents the typical interstitial
matrix microenvironment of endothelial cells during physiological
angiogenesis in vivo [24,25] and our experiments were not subject
to batch variation. The -BD11 decellularized matrix provided an
autonomous human serum-free microenvironment to better
explore angiogenic responses to matrix components.
Serum deprivation was toxic for hMSC-TERT20-BC8 cells but
surprisingly not for -BD11 cells. Primary human mesenchymal
stem cells were susceptible to death after hypoxia but much more
so when combined with serum starvation [26]. Mechanisms
underlying the survival of the -BD11 cells will be the focus of
future studies. An attractive hypothesis is that starved hMSC resist
stress by adopting a ‘‘default’’ subsistence phenotype that
encourages new vessel growth. The adaptive response to serum
starvation may include expression of hypoxia-inducible mRNAs
regulated by changes in translation efficiency [27]. Supporting this
view, -BD11 cells underwent a 4-fold increase in translation
protein eIF4G/eIF4E ratio when starved of serum, likely to reflect
reduced 4E-BP levels [28]. Stable knockdown of 4E-BP1 can
contribute to expression of proteins associated with cytoskeletal
organization, invasion and hypoxia-regulated genes [29]. Eluci-
dating such mechanisms has implications for both tumour biology
and stem cell therapy, given that ex vivo preconditioning via
hypoxia improved ischemic therapy with human mesenchymal
stem cells [30].
Notably, among the genes expressed during -BD11 serum-free
cord morphogenesis, were relatively low levels of CD31 and
VEGFR-2, but Angiopoietin-1 (Ang-1) distinguished these cells
from TIME microvascular endothelial cells, emphasizing a more
pericyte than endothelial phenotype. In addition, gene expression
for the Ang-1 receptor Tie-2 has been attributed to a
mesenchymal subpopulation of pericyte progenitors [31]. Blood
vessels of Tie-2 knockout mice lacked mural cells and a similar
poor endothelial cell association with mesenchymal cells and
surrounding matrix was seen in Ang-1 knockouts. The manner in
which Ang-1 is presented to the endothelial cells has an important
influence on subsequent Tie-2 mediated signalling pathways. For
Figure 4. Histological sections of MESA plugs after 7 days in vivo. A: Photomicrograph of a MESA implant showing a 1 cm diameter matrigel
plug with a centrally implanted sponge (arrow, ‘‘S’’). B: Haemotoxylin and Eosin stain of a sponge loaded with ECBM-MV2 medium. C,D: Histological
sections stained with murine specific anti-CD34 antibody visualized by brown chromogen diaminobenzidine. C: Field of view of matrigel adjacent to
sponge seeded with -BC8 cells. D: Field of view of matrigel adjacent to sponge seeded with -BD11 cells. E: Chalkley count quantification of vasculature
adjacent to the MatrigelH embedded sponge. *P,0.05, Kruskal-Wallis. F,G: Histological sections showing migratory cells within the MatrigelH
surrounding F, control medium sponges or G–I: sponges with -BD11 decellularized matrix, stained blue with Masson’s trichrome. H,I: Anti-CD34
antibody was used to visualize endothelial cells (brown) in regions of the MatrigelH I: with or H: without decellularized matrix. Scale bar, 100 mm.
doi:10.1371/journal.pone.0021888.g004
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Protein name Accession number Gene symbol
Cellular
location
1
Evidence for role in
angiogenesis [Reference]
Activated leukocyte cell
adhesion molecule (CD166)
IPI00015102.2 ALCAM PM Targeted Antibodies diminished endothelial
capillary formation induced by Galectin-8 [83]
Aminopeptidase
N (CD13)
IPI00221224.6 ANPEP PM Knockout mice show impaired angiogenesis
[51]
CD44 Antigen
precursor
IPI00305064.1 CD44 PM Mediates activity of antiangiogenic peptide
[57]
CD47 IPI00413696.5 CD47 PM Thrombospondin-1 receptor, antagonises
nitric oxide [84]
Enolase 1 IPI00465248.5 ENO1 PM A hypoxia-induced protein in endothelial cells
[85]
Epidermal Growth
factor receptor
IPI00018274.1 EGFR PM Important for angiogenic factor secretion by
MSC [86]
Glycoprotein non
metastatic protein B
IPI00470529.3 GPNMB PM Shed ectodomain enhances endothelial
recruitment [49]
Insulin Like Growth
Factor 2 receptor
IPI00289819.4 IGF2R PM Mediates endothelial progenitor cell homing
[87]
Integrin alpha-2
precursor
IPI00013744.1 ITGA2 PM Mediates endothelial ex vivo capillary
morphogenesis [88]
Integrin alpha-3
precursor (CD49c)
IPI00290043.1 ITGA3 PM Alpha3beta1 integrin mediated inter-cell
crosstalk for endothelial migration [89]
Integrin alpha-5 precursor IPI00306604.5 ITGA5 PM Targeting siRNA caused vessel shrinkage [90]
Integrin alpha-6
precursor (CD49f)
IPI00010697.1 ITGA6 PM Increased expression in angiogenic tumour
vessels [91]
Integrin alpha-V precursor (CD51) IPI00027505.2 ITGAV PM An anti-angiogenic target [90]
Integrin beta 1 precursor IPI00217563.3 ITGB1 PM Gene inactivation via Cre-loxP in mice caused
mural cell defects [92]
Integrin beta 3 precursor IPI00303283.2 ITGB3 PM Antibody reduced adhesion of MSC to
endothelium [59]
Integrin beta 5 precursor IPI00788112.1 ITGB5 PM Overexpression enhanced angiogenic cell
function [93]
Metadherin IPI00328715.4 MTDH PM Mediates breast cancer cell adhesion to
endothelium [94]
Neuropilin 1 IPI00398715.5 NRP1 PM Receptor for angiogenic factors [95]
Nucleolin IPI00444262.3 NCL PM Mediates cell migration and tubule formation
in angiogenic vessels [96]
Platelet-derived growth factor
receptor beta precursor
IPI00015902.3 PDGFRB PM Targeted antibodies prevented MSC tubule
formation on matrigel [97]
Pro low-density lipoprotein receptor
related protein 1 precursor (CD91)
IPI00020557.1 LRP1 PM Regulates ECM in blood vessel formation and
stabilization [98]
Semaphorin 7A IPI00025257.1 SEMA7A PM Binds integrins, promotes axon outgrowth [95]
Talin-1 IPI00298994.5 TLN PM Maintains integrin complexes interacting with
VCAM-1 [99]
Tetraspanin IPI00298851.4 CD151 PM Complexes with integrins to enhance
angiogenesis [100]
Thy-1 cell surface
antigen (CD90)
IPI00022892.2 THY1 PM Cytomegalovirus induced down regulation led
to vascular disease [101]
Annexin A2 IPI00455315.4 ANXA2 ECM Interacts with pro-angiogenic S100A4 protein
[102]
Basigin (CD147) IPI00795150.1 BSG/EMMPRIN ECM Stimulates endothelial cell migration and tube
formation [103]
Cathepsin S IPI00299150.4 CTSS ECM Promotes pericellular hydrolysis and targeted
antibodies inhibited angiogenesis [55]
collagen, type VI, alpha 1 IPI00291136.4 COL6A1 ECM Associated with tumour stroma and matrix
remodelling for microvasculature [104]
collagen, type VI, alpha 2 precursor IPI00304840.4 COL6A2 ECM ibid
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migration through Erk signaling pathways, but associated with
cell-cell interactions, Tie-2 bridged adjacent cell junctions and
Ang-1 preferentially activated endothelial Akt signaling, stimulat-
ing vascular quiescence. Thus, Ang-1 could modulate endothelial
cell sprouting and control vascular quiescence and stabilization
[32][33]. Consistent with expression of pericyte genes, -BD11 cells
were histologically located adjacent to endothelial cells in vivo.
Cell clone differences governing cell survival may overshadow
those governing angiogenic potency and complicate data inter-
pretation. Thus we focused on the most angiogenic clone for
proteomic characterisation to account for -BD11 cord network
formation and interaction with endothelial cells. SILAC proteome
analysis selectively detected -BD11 synthesized proteins, overcom-
ing the problem of artefactual identifications from any contam-
inant serum proteins. We identified intracellular proteins likely to
be involved in -BD11 cord formation and cell surface molecules
likely to mediate chemoattractive recruitment, cell-cell interactions
and activation of endothelial cells. Among SILAC-labelled
intracellular proteins co-purified with the -BD11 decellularized
matrix, PKCd could be induced by serum deprivation and
activated cell scattering [34]. Angiogenic GTPase signaling
molecules, such as IQGAP1 could interact with VEGFR-2 [35]
and Rap1b, an integrin activating molecule, could induce
angiogenic sprouting [36]. Chloride Intracellular Channel 4
(CLIC4) was also implicated in early stages of endothelial tubular
morphogenesis by proteomic studies [37]. The autonomous -BD11
cell sprouting upon serum starvation challenged traditional
‘‘endothelial first’’ angiogenic models whereby pericytes are
recruited by migrating endothelial cells that lead the tubulogenic
process. Our ex vivo response of endothelial cells to -BD11
decellularized matrix was consistent with in vivo observations that it
Protein name Accession number Gene symbol
Cellular
location
1
Evidence for role in
angiogenesis [Reference]
collagen, type VI, alpha 3 precursor IPI00022200.2 COL6A3 ECM ibid
Elastin microfibril
interfacer 1
IP100013079.1 EMILIN1 ECM Knockout mice have vascular defects [105]
Fibronectin 1 isoform
4 preprotein
IPI00414283.5 FN1 ECM Promotes brain endothelial cell survival and
growth [106]
Fibulin-1 IPI00218803.2 FBLN1 ECM Binds angiogenin, stabilizes new blood vessel
walls [107]
Galectin-1 IPI00219219.3 LGALS1 ECM Essential for tumor angiogenesis [73]
Galectin-3 binding protein IPI00023673.1 LGALS3BP ECM Implicated as an angiogenic factor from gene
expression data mining [108]
Laminin B1 IPI00853454.1 LAMB1 ECM Increases endothelial sprout formation [91]
Matrix Metalloproteinase-1 IPI00008561.1 MMP1 ECM Inducible by hypoxia in human bone marrow
MSC [109]
Matrix Metalloproteinase-3 IPI00027782.1 MMP3 ECM Upregulated by hypoxia in MSC [109]
Matrix Metalloproteinase-14 IPI00218398.5 MMP14 ECM Plays a critical role in MSC-mediated sprouting
[56]
Perlecan IPI00024284.4 PLC ECM Impaired angiogenesis in Perlecan deficient
mice [110]
Tenascin C IPI00220213.1 TNC ECM Mediator of postnatal cardiac angiogenesis
[111]
Thrombospondin-1 IPI00296099.6 THBS1 ECM Negative modulator of angiogenesis, activates
latent TGF-ß1 [40]
Transforming growth
factor beta induced
IPI00018219.1 TGFBI ECM Mediates lymphatic endothelial cell adhesion
to ECM in low oxygen [112]
Transglutaminase 2 IPI00218251.1 TGM2 ECM Autoantibodies disturb angiogenesis [113]
Versican isoform 1 IPI00009802.1 VCAN ECM Versican G3 domain promotes angiogenesis
[114]
High Mobility Group Box 1 IPI00419258.4 HMGB1 S An angiogenic switch molecule [50]
HtrA1 Serine Peptidase 1 IPI00003176.1 HTRA1 S Mutated in single gene disorder of cerebral
small vessels CARASIL [115]
Lactadherin IPI00002236.3 MFGE8 S Binds integrins with a crucial role in VEGF-
mediated neovascularization [116]
Macrophage migration
inhibitory factor
IPI00293276.1 MIF S Chemotactic for endothelial progenitor cells
[117]
Phosphoglycerate kinase I IPI00169383.3 PGK1 S Secretable glycolytic enzyme regulated by
CXCR4 [118]
Wingless type MMTV integration site
member 5A
IPI00013178.5 WNT5a S Regulates human endothelial cell proliferation
and migration [119]
1PM=Plasma Membrane, ECM=Extracellular Matrix, S=Secreted.
doi:10.1371/journal.pone.0021888.t001
Table 1. Cont.
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21888Figure 5. Endothelial cell attachment to decellularized matrix ex vivo required -BD11 Galectin-1 expression. A: RT-PCR analysis of
LGALS1 gene expression in -BD11 cells grown in MEM with 10% FBS (day 0) versus serum starved cells treated with control siRNA (siControl) or anti-
Galectin-1 siRNA (siLGALS1). B: Western blot of Galectin-1 protein expression in -BD11 cells grown in MEM with 10% FBS (day 0) versus cells serum
starved for 3 days (clear bars). C: Western blot analysis of Galectin-1 protein in serum starved -BD11 cells 3 days after transfection with anti-LGALS1
siRNA (siLGALS-1) or control siRNA (siControl), versus routinely cultured TIME cells. D–G: Phase contrast photomicrograph of -BD11 cell monolayers
grown D,E: with 10% FBS or F,G: without serum three days after treatment with D,F: control siRNA or E,G: anti-LGALS1 siRNA. H: Growth of -BD11 cells
in 10% FBS (N,m) or without FBS (#,n) after transfection with control siRNA (#,N) or anti-LGALS1 siRNA (n,m). * p,0.05. I–L: Phase contrast
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existing capillaries and endothelial cells use these ‘‘cellular cables’’
as guidance cues during their movement to complete vessel
assembly [38]. Others have also noted that pericytes can bridge
gaps between the leading edges of opposite endothelial sprouts,
implicating they may serve as guiding structures for outgrowing
endothelial cells [39].
An early role for pericytes would be advantageous for
therapeutic application and our finding that hMSC decellularized
matrix per se effectively enhanced neoangiogenesis in vivo was very
encouraging. This was not a foregone conclusion, since both
positive and negative interactions balance vascular ECM mor-
phogenesis or regression and some stromal cell types induced
apoptosis when they interacted with endothelial cells [40]. The
host remodeling response is sensitive to matrix preparation [41];
chemically crosslinked matrix scaffolds can resist degradation,
inducing fibrous encapsulation and chronic inflammation rather
than constructive remodeling. We did not attempt to retain
tertiary structure when harvesting the decellularized matrix, given
that degradation products of matrix bioscaffolds sufficed as
modulators of recruitment and proliferation of endothelial cells
[42]. Nor did we explore whether -BD11 decellularized matrix
sequestered potent angiogenic factors such as VEGF and FGF-2,
but for Sorrell et al. these cytokines did not explain the different
angiogenic potency of ECM from different human dermal
fibroblast subpopulations [43].
Surprisingly, we did not detect collagen type I in the
decellularized matrix extracts [44] though we have independent
evidence -BD11 cells secreted this collagen (data not shown). It is
possible that in -BD11 cord morphogenesis collagen-I is expressed
at relatively low levels. Soucy and Romer [45] noted that the
compact arrangement of tenascin-C and collagen-VI filled more
volume than collagen-I and endothelial cell matrix adhesions
selectively targeted fibronectin. We detected tenascin-C, fibronec-
tin and all three monomer chains of collagen-VI required for the
triple helix structure that defines the locus of endothelial cell
interaction [46]. Of special relevance, collagen-VI differed from
collagen-I by being able to prevent apoptosis and allow
proliferation of mesenchymal cells under serum-starved conditions
[47].
Qualities attributed to decellularized matrix in a therapeutic
engineered airway included a contribution to revascularization
[48]. The -BD11 decellularized matrix compared well to whole
cells with regard to neoangiogenic potency in the MESA assay.
How could a cell attachment scaffold provide a near-equivalent
response to whole cells that can also synthesize and secrete
angiogenic chemokines? The proteomic characterization provided
a more understandable view, with molecules that sequester growth
factors and remodel matrix to dynamically govern the recruitment
of endothelial cells, their interaction and activation to form tubular
structures. The -BD11 decellularized matrix contained GPNMB,
which shed from the cell surface by the matrix metalloproteinase
ADAM10 enhanced recruitment of endothelial cells [49]. SILAC
labelled ADAM10 was found in -BD11 supernatant (data not
shown). The secreted form of HMGB1 has been shown to be
sequesterable in ECM, able to recruit endothelial cells and
stimulate sprouting [50]. APN is a membrane bound zinc-binding
protease that participates in extracellular proteolysis with context
dependent function. Though not essential for survival or
physiological vascularization, APN-null mice showed a severely
impaired angiogenic response to pathological conditions [51].
MMP1, MMP3 and MMP14 functions are not confined to the
degradation of ECM components, but include activation of latent
cytokines, cleaving membrane-anchored proteins and release of
matrix-bound growth factors, generating bioactive neopeptides.
The membrane-type family member MMP14, also known as
MT1-MMP is one of the most influential metalloproteinases in the
angiongenic process [52]. Cathepsins can cooperate with MMPs
[53] and Cathepsin-S, enriched in sprouting tip cells [54] is
required for angiogenesis [55]. In addition to specific mesenchy-
mal cell proteolytic mechanisms [56], paracrine proteases from
endothelial cells and local inflammatory cells also remodel the
ECM during the vascular response, releasing chemokines [6].
CD44 is a cell surface proteoglycan that serves as a cognate
receptor for MMP-9 and targeting the CD44 pathway inhibited
endothelial migration and tubule formation more than endothelial
proliferation [57].
The contribution of transmembrane a and ß heterodimer
integrins (the most important receptor family mediating cell
adhesion to ECM) to endothelial-pericyte interactions has been
extensively reviewed [58]. The integrin subunits expressed by the
-BD11 cells were in broad agreement with those described for
primary MSC-endothelial cell interactions [59]. We also found
modulators of integrin function, such as integrin ß1 binding
semaphorin 7A [60] and Talin-1, a focal adhesion complex
protein that regulates integrin interactions and controls pericyte
contractility [61]. The stress response to serum starvation or
hypoxia has been shown to modify integrin expression and
function to favor ECM-cell interactions [62].
Regarding molecules that can sequester angiogenic cytokines,
neuropilin-1 is a co-receptor for VEGF165 that can also bind
Galectin-1 resulting in enhanced VEGFR-2 phosphorylation, to
mediate migration and adhesion in endothelial cells [63]. Perlecan
can bind many growth factors including BMP-2, CTGF, PDGF,
FGF-2, nidogen1, nidogen2, a-dystroglycan and VEGF. It may
create stable ‘‘signalosomes’’ by clustering transmembrane proteins
and stabilizing their interactions. It also interacts with the a2ß1 cell
surface integrin forming additional complexes linking ECM with
the cell. The outcome of perlecan antisense targeting is context
dependent; in human colon cancer xenografts it decreased
neovascularization and tumor progression, whereas, in fibrosarco-
ma cells, the phenotype became more aggressive with increased
migration and invasion [64].
Consistent with the long held view that there is dynamic
reciprocity between matrix composition and gene expression [65],
a number of SILAC labelled ECM proteins are also found
intracellularly [66]. Dual localization proteins include EGFR,
HMGB1, PDGFR, LGALS1, Nucleolin, ANXA2, TGM2 and
MIF. Location can influence function; extracellular TGM2 can
have a role in cell adhesion, whilst intracellular TGM2 can
regulate apoptosis [67]. Confirming a cell surface role for
nucleolin, blocking antibodies could suppress angiogenesis [68].
photomicrograph of -BD11 decellularized matrix from 3 days serum-starved cultures of cells transfected with I,K: siControl or J,L: siLGALS1 I,J: before
seeding with TIME endothelial cells and K,L: 30 minutes after seeding. M,P: ImageJ software rendition of endothelial cell distribution in
645.6 mm6433.5 mm fields used to determine spatial point coordinate data for endothelial cells seeded on matrix from -BD11 cells treated with M,:
siControl or N,P: siGALS1. Ripley’s K function graphs for Time endothelial cell distribution on decellularized matrix from -BD11 cells treated with O:
siControl or P: siLGALS1. Q,R: Photomicrographs of Time cells 10 days after seeding on decellularized matrix from -BD11 cells treated with Q: siControl
or R: siLGALS1. Scale bar, 100 mm.
doi:10.1371/journal.pone.0021888.g005
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emphasizing need for functional studies.
A protein with an important angiogenic role might be expected
to persist or even have increased expression during starvation
stress. Galectin-1, a highly expressed protein in primary hMSC,
was strongly implicated in ECM-cell interactions [20]. Correlating
with our serum-starved situation, in hypoxic stress conditions,
fibroblasts expressed increased levels of Galectin-1 [69]. Whether
Galectin-1 promotes or inhibits cell growth is context dependent
[70]. Notably, -BD11 cells became more dependent on Galectin-1
for optimal growth when starved. Though siLGALS1 treated
-BD11 cells retained an initial cord-morphogenesis response to
serum starvation, qualities of the ECM were altered and
subsequent preferential attachment of endothelial cells to the
decellularized matrix was lost. Thus, Galectin-1 expression in the
hMSC maintained a role modulating ECM-heterotypic cell
interactions [20],[71]. Given these results, we used lentiviral
vector shRNA GALSN1 transfection for more stable knock down
to explore whether Galectin-1 also served as an effective tumour
target in our -BD11 model. Surprisingly, -BD11 tumour growth
from pooled colonies of transfected cells was not markedly affected
despite a greatly reduced recruitment of host endothelial cells to
the tumour mass. Heterogeneity in the microvascular density of
-BD11 tumours was previously reported [12] and sarcomas may
develop alternative means of circulation [5]. Histological analysis
did detect nuclear Galectin-1 in the tumour cells, a phenotype
similar to the persistence of nuclear nucleolin expression in the
presence of its inhibitors of transcription and translation [72], but
cell surface matrix expression of Galectin-1 was below detection.
Perhaps arising from use of a heterogenous pool of transfected
-BD11 cells we did observe a small exceptional region where the
human cells expressed Galectin-1 in the matrix. Murine
endothelial cells populated this region densely, confirming an in
vivo requirement for -BD11 surface galectin-1 expression for
endothelial interaction.
Recent studies have verified that Galectin-1 [73,74] and other
proteins identified in -BD11 ECM, e.g. aminopeptidase-N [75]
annexin-A2 [76] or nucleolin [77], can serve as tumour targets,
with evidence that combined targeting of perivascular and
endothelial cells can enhance anti-tumour treatment [78]. Models
Figure 6. Endothelial cell association with -BD11 cells in vivo required matrix Galectin-1 expression. A: RT-PCR analysis of LGALS1 gene
expression in pooled populations of -BD11 cells transfected with shRNA lentiviral vectors targeting a scrambled sequence (Control shRNA) or
Galectin-1 (LGALS1 shRNA). B–J: Histomorphology of -BD11 transfectant tumour sections immunohistochemically stained (brown) for B: Galectin-1 in
cells transfected with control shRNA or C: Galectin-1 in cells transfected with LGALS1 shRNA. D: CD34 immunohistochemical staining targeted murine
endothelial cells in a parallel serial section equivalent to C. E: Whole tumour section of -BD11 cells transfected with LGALS1 shRNA with neighbouring
subregion immunohistochemically stained for CD34 (arrow). F–H: Higher power magnification of arrow region in E, stained for F: CD34, G: Human-
specific CD99, H: Galectin-1. Higher power magnification of Galectin-1 staining in regions in H that were I: CD99+/CD342 and J: CD99+/CD34+. Scale
bar, 100 mm.
doi:10.1371/journal.pone.0021888.g006
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implications for understanding the regulation of key angiogenic
processes in tumorigenesis and ischemia. In a broader context,
extracellular matrix bioactive peptides may have direct therapeutic
application [79]. Decellularized matrix arguably provides lower
clinical risks regarding immune rejection and tumorigenicity
compared to whole cells. Yet biological effectiveness can vary
greatly between similar sources or with just single gene alterations.
Detailed understanding of decellularized matrix and its compo-
nents is required for improved therapeutic application.
Materials and Methods
Cell culture
The hMSC-TERT20 clones, designated hMSC-TERT20-BC8
and hMSC-TERT20-BD11 and TIME cells were derived and
cultured as described [11] in MEM (Gibco Invitrogen Co.,
Tastrup, Denmark) supplemented with 10% fetal bovine serum
(FBS; Gibco Invitrogen Co., batch tested) or supplemented
ECBM-MV2 medium (PromoCell GmbH, Heidelberg, Germany),
respectively.
Serum Starvation
hMSC-TERT20-BC8 and -BD11 cells were routinely cultured
to 90% confluence in 6-well plates. After three washes with PBS
++
(Gibco Invitrogen) cells were fed serum-free MEM (Gibco
Invitrogen Co., Tastrup, Denmark) and re-fed every 3 days. At
indicated time points, RNA was harvested for RT-PCR gene
expression analysis, or cells were pelleted for Western blot analysis,
fixed in 4% formaldehyde for immunocytochemistry, or detached
with trypsin for FACS analysis.
RNA extraction and reverse-transcriptase
polymerase-chain reaction (RT-PCR)
Total RNA isolated from cultured cells used a single-step
TrizolH (Invitrogen Co., Tastrup, Denmark) method, following
manufacturer’s instructions. RT-PCR used 20 pmole of forward
and reverse primers (Table 2) as described [15]. PCR products
were analyzed by 1.5% agarose gel electrophoresis, visualized with
ethidium-bromide, and photographed.
Western blot analysis
At indicated time points, cells were washed twice with PBS
containing CompleteH protease inhibitor cocktail (Roche), scraped
as whole cells and spun at 250 g for 15 minutes at 4uC before
snap-freezing and storage at 2180uC. Samples were resuspended
in 100–200 mL lysis buffer (50 mM Tris/HCl, pH 7.5, 1 mM
Na4P2O7, 1% Triton X-100, 2 mM EGTA, 2 mM EDTA-Na).
Lysates sheared through a 26-guage needle, had total protein
quantified by DC protein assay (Biorad, Munich, Germany).
Equivalent samples (10 mg protein) and SeeBlue Plus2 pre-stained
molecular size markers (Invitrogen) were loaded onto 4–12% Bis-
Tris NuPage gels (Invitrogen) and run under denaturing
conditions in NuPage MOPS-SDS buffer (Invitrogen). Proteins
transferred to Invitrolon-PVDF filters in NuPage transfer buffer
overnight at 4uC were incubated with blocking buffer SEA
BLOCK (Pierce) for 1 hour at 4uC. Primary antibodies were
applied for 1–3 days at 4uC, then secondary antibodies for 1 hour
at 21uC. Immunoreactive proteins were detected with Q-dot
Western blot reagent kits (Invitrogen) and ECL Plus Western
blotting reagents (GE Life Sciences) per manufacturers’ instruc-
tions and exposed to Hyperfilm ECL (GE Life Sciences). The
diluted antibodies were mouse anti-human CD146 (NCL-CD126;
Novocastra) at 1:250, rabbit anti-human beta-actin (4967, Cell
Signaling) at 1:1000, rabbit anti-human profilin (IG706, Immu-
noglobe) at 1:1000, mouse anti-human beta-actin (6276, Abcam)
at 1:5000, anti-mouse IgG1-HRP (7076, Cell Signaling) at 1:2000
and anti-rabbit IgG-HRP (7074, cell Signaling) at a 1:2000.
In vivo Matrigel Encapsulated Sponge Angiogenesis
(MESA) assay
A polyvinyl alcohol (PVA) 2 mm
3 sponge (PVA unlimited,
Warsaw, IN, USA) seeded with 1610
5 cells in serum supplement-
ed medium was incubated overnight at 37uC, 5% CO2 in a 96-
well ultra-low adhesion plate (Corning). Alternatively, sponges
were cultured in medium alone, or centrifuged with decellularized
matrix from 1610
6 cells serum-starved for 24 hours. Adopting a
previous assay [80] and following institutional guidelines, 600 mlo f
cold growth factor reduced Matrigel (BD biosciences) was injected
subcutaneously in 8-week old NOD/SCID mice to solidify within
20 minutes at body temperature. Needle orientation parallel to
the tail improved plug geometry and uniformity. After a small
skin incision, the treated PVA sponge was implanted centrally
in the matrigel plug. After skin suture, mice were kept in an
environment–controlled facility. At 7 days, 2.5 mg FITC-Dextran
(Sigma) in 200 mL saline was injected in the tail vein, three minutes
before sacrifice. The extracted matrigel/sponge pocket was fixed
in 4% buffered formaldehyde for 24 hours at 4uC. Paraffin
Table 2. Primers used for RT-PCR.
Gene Forward primer Reverse primer
Annealing
temp. (6C)
Amplicon
size (bp)
Ang-1 59-GCCATTACCAGTCAGAGGCAG-39 59-AATAGGCTCGGTTCCCTTCC-39 60 70
Ang-2 59-CGCTCGAATACGATGACTCG-39 59-CCACTGAGTGTTGTTTTCCATGAT-39 60 72
Tie-1 59-ACTTCACTTACGCGGGCATT-39 59-GCCACGTTCTGGCTGGAT-39 60 68
Tie-2 59-GGCAACTTGACTTCGGTGCT-39 59-GGCCTTGGTGTTGACTCTAGCT-39 60 80
CD105 59-CGCACCGATCCAGACCACTC-39 59-CCCGGCTCGATGGTGTTGGA-39 60 188
CD31 59-AAGGTCAGCAGCATCGTGG-39 59-AGTGCAGATATACGTCCC-39 60 224
VEGF-A 59-CTACCTCCACCATGCCAAGTG-39 59-TGATTCTGCCCTCCTCCTTCT-39 55 62
VEGFR-2 59-TGCCACCTCCATGTTTGATG-39 59-CAGCTGGAATGGCAGAAACTG-39 60 188
LGalS1 59-GGGTGGAGTCTTCTGACAGC-39 59-CTTGCTGTTGCACACGATG-39 60 250
ß-actin 59-TGTGCCCATCTACGAGGGGTATGC-39 59-GGTACATGGTGGTGCCGCCAGACA-39 60 430
doi:10.1371/journal.pone.0021888.t002
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antibodies for human specific CD31, clone JC/70A at 1:50
dilution (Dakocytomation, Denmark), a-Smooth Muscle Actin,
clone 1A4 at 1:200 dilution (Dakocytomation, Denmark), human
specific CD99, clone 12E7 at 1:100 dilution (Dakocytomation,
Denmark), mouse specific CD34, clone MEC14.7 at 1:200
(Abcam ab8158) and Rabbit anti-FITC, polyclonal antibody at
1:200 dilution (Dakocytomation, Denmark). Masson’s trichrome
stained matrix collagen fibres blue in samples using decellularized
matrix. Murine microvessel quantification [12] used a 25-dot
Chalkley microscope eyepiece graticule aligned with the sponge
edge at 6200 magnification.
Culture of endothelial cells on decellularized hMSC
matrix
Clones hMSC-TERT20-BD11 and -BC8 were seeded at 10.000
cells/cm
2 in 6 well plates in standard medium. After overnight
attachment, cells were washed twice with PBS (Sigma/Gibco)
before changing to serum-free MEM containing 1% P/S
(Invitrogen). After 3 days of serum starvation, the monolayer
placed on ice was washed in ice cold PBS
22 containing EDTA
+
CompleteH protease inhibitors (Roche). The cells were decellular-
ized [19] for 3–5 minutes with 0.25% Triton X (Fluka), 0.25%
sodium-deoxycholate (Merck) in PBS
22 (Gibco), and the isolated
ECM was gently washed in PBS
++(Gibco) with 100 mg/mL
RNAse A (Roche) and 10 IU/mL DNAse (Sigma) followed by
three washes in PBS
++. Morphological changes were observed
under phase-contrast illumination using an inverted microscope
(Olympus) connected to a digital camera (Olympus, Denmark).
Visual inspection ensured derivation of extracellular matrix
without Hoechst dye-stained intact nuclei. For three independent
hMSC matrix preparations, TIME cells (10.000 cells/cm
2) were
seeded on the matrix and the distribution of bright round
refractive freshly attached cells was photographed after 30 min-
utes. Images were processed using ImageJ software to analyse a
fixed window size of 645.6 mm6433.5 mm with thresholds
isolating bright cells with points defined by intensity maxima.
Ripley’s K(t) function; K (t)=l21 E [ number of extra Events
within distance t of a randomly chosen event], where l is the
intensity (number per unit area) was used to statistically summarize
the point pattern, testing the hypothesis that under control
conditions the endothelial distribution was not random, but
covariant with the underlying decellularized matrix pattern.
Mass spectrometry evaluation of hMSC-derived
decellularized matrix proteins
In-Solution Digest. Decellularized matrix from hMSC-
TERT20-BD11 cells was solubilized in 6 M urea/2 M thiourea
(pH 8.0), 10 mM Tris pH 8.0. Proteins were reduced in 1 mM
DDT (Sigma) for 45 minutes at room temperature and S-
carbamidimethylated in 5.5 mM iodoacetamide (Sigma) in
50 mM NH4HCO3 for 30 minutes in the dark. Overnight
protein digestion with 1 mg LysC at room temperature was
followed by 46 dilution in 50 mM NH4HCO3 and addition of
1 mg trypsin (Sequencing grade, Promega) for overnight digestion
at room temperature. The peptides were acidified with 3% (final
concentration) trifluoracetic acid, then desalted and concentrated
on C18 reverse-phase material micro-columns (Empore Disc, 3 M)
[81].
Fourier transform mass spectrometry. A 7-Tesla LTQ-
TF instrument (Thermo Fisher) coupled to an Agilent 1100
nanoflow liquid chromatography (LC) system (Agilent
Technologies) provided LC tandem mass spectrometry (LC-MS/
MS). The LC reverse-phase column was packed with ReproSil-
Pur 120 C18-AQ 3 mm resin (Dr Maisch, GmbH). The mass
spectrometer was operated in data dependent acquisition mode,
the three most intense spectrum ions from selected ion monitoring
(SIM) scans were chosen for accurate mass measurement.
Data analysis. Protein identification was via the MASCOT
Search Engine (Matrix science). The major search criteria were as
follows; Database: MSIPIslim_human (68992 sequences) [82].
Enzyme: MSIPI_DPTrypsin, allowing two missed cleavages. Fixed
modification: Carbamidomethyl (C). Variable modifications:
Acetyl (Protein N-term), Ammonia-loss (N-term C), GlnRpyro-
Glu (N-term Q), GluRpyro-Glu (N-term E), Oxidation (M), and
Oxidaiton (P). MS/MS tol.: 0.8 Da. Peptide tol.: +/22 ppm. The
MSQuant v. 1.4.3a31 program (open source www.msquant.
sourceforge.net) was used to set filters and manually validate
protein identification. Identification criteria were: peptide length:
at least 7 amino acids, at least two unique peptides with a Mascot
score $25. Protein lists and additional GO information was
collected using ProteinCenter software (Proxeon Biosystems A/S,
Odense, Denmark).
Immunofluorescent staining and Confocal Microscopy
Cells grown on glass chamber slides (Nunc, Denmark) were
fixed in buffered 4% paraformaldehyde for 10 minutes at room
temperature, washed 63 with PBS (Sigma Aldrich) and incubated
for 1 hour with primary antibodies in ChemMate Antibody
diluent (Dakocytomation, Denmark). Human specific TRA-1-85
antibody (Chemicon) was diluted 1:300, Anti a-smooth muscle
actin, clone 1A4 (Dakocytomation, Denmark) was diluted 1:200.
Non-specific FC receptors were blocked with goat serum (Zymed,
San Francisco, California, US) for 30 minutes. Slides were washed
63 in PBS and incubated for 1 hour with compatible secondary
antibodies (ALEXA Flour 555 and 488 Molecular Probes, USA),
before mounting in DAPI medium (Dakocytomation, Denmark).
A Zeiss LSM 510 META confocal laser-scanning microscope
obtained images with a 636/1.2 W corr objective used an argon
laser (488 nm) for excitation of Alexa 488, HeNe laser 543 nm for
excitation of Cy3 and Alexa 555 and a two-photon (MaiTi XF-
W2S) laser at wavelength 780 nm for excitation of DAPI. Pinholes
for the HeNe laser and Argon laser were set to 1. Images were
processed using NIH ImageJ 1,37c (http://rsb.info.nih.gov/ij/).
The z-project feature and Aling3-TP plug-in for ImageJ made 3D
reconstruction ortho images from 0.49 mm interval z-stacks.
Transient siRNA Targeting of Galectin-1
ON-TARGETplus SMARTpool siRNA (Thermo Scientific)
containing a mixture of four SMARTselection-designed siRNAs
targeted the human Galectin-1 gene, LGALS1. The sense
sequences of anti-LGALS1 siRNA were: 59-CUAAGAGCUUC-
GUGCUGAA-39;5 9-ACGGUGACUUCAAGAUCAA-3; 5-CC-
AGCAACCUGAAUCUCAA-39;5 9-GCUGCCAGAUGGAUA-
CGAA-39. Corresponding scrambled siRNA served as control and
the same short strands of siRNA coupled with fluorescein were
used to confirm successful transfection. The final concentration of
the siRNA duplex stock solution, dissolved in Dharmacon 56
siRNA buffer was 20 mM. Clone hMSC-TERT20-BD11 cells
were reverse-transfected by seeding 2610
5 cells onto siRNA:Li-
pofectamine 2000 (Invitrogen) complexes according to manufac-
turer’s instructions. After overnight incubation the medium was
changed to antibiotic and serum-free MEM. The mRNA and
protein expression levels of Galectin-1 were evaluated during the
first 3 days post-transfection. Cell number was counted from
triplicate wells using a Nucleocounter (Chemometec A/S) per
manufacturer’s instructions. Decellularized matrix from siRNA
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above, for testing interaction with newly-seeded TIME endothelial
cells.
Stable shRNA Targeting of Galectin-1 with lentiviral
transfection
Cloning shRNA into Lentiviral Vector: Oligo Se-
quence. The following oligos were cloned into the pSicoR
PGK puro vector (PMID: 15240889, Addgene): Non-targeting/
scrambled, 59TGAAGGCCAGACGCGAATTATTCAAGAGA-
TAATTCGCGTCTGGCCTTCTTTTTTC-39 sense, 59TCGA-
GAAAAAAGAAGGCCAGACGCGAATTATCTCTTGAATA-
ATTCGCGTCTGGCCTTCA-39 antisense; target sequence GA-
AGGCCAGACGCGAATTA. LGALS1, 59 TGCTGCCAGAT-
GGATACGAATTCAAGAGATTCGTATCCATCTGGCAGC-
TTTTTTC-39 sense, 59 TCGAGAAAAAAGCTGCCAGATGG-
ATACGAATCTCTTGAATTCGTATCCATCTGGCAGCA-39
antisense; target sequence GCTGCCAGATGGATACGAA (PMID:
18431251).
Oligo Annealing, 59phosphorlation. Oligos were first
annealed by adding 1 nmol of sense plus antisense oligo, to 5 mL
106annealing buffer (1 M Tris-HCl (pH 7.5), 5 M NaCl, 0.5 M
EDTA) adding water to reach a total volume of 50 mL. The
solution was incubated at 95uC for 4 minutes, 70uC for
10 minutes and cooled slowly to 20uC. For 59phosphorlation,
100 pmol annealed Oligos was added to 2 mL1 0 6 T4 ligase
buffer (Promega) and 10 units of T4 Polynucleotide Kinase
(Promega) with water to a total volume of 20 mL. The solution was
then incubated at 37uC for 30 minutes and 70uC for 10 minutes.
Digestion, dephosphorylation of vector and
ligation. 1 mg of pSicoR PGK puro vector was digested with
XhoI and HpaI (Promega) then 1 unit of TSAP (Thermosensitive
Alkaline Phosphatase, Promega) was added. The solution was
incubated at 37uC for 15–30 minutes and TSAP was heat
inactivated at 74uC for 15 minutes. Ligation was done by
adding 50 ng of pSicoR PGK puro vector to 0.25 pmol
annealed and 59phosphorylated oligo, 5 mL2 6 Rapid LigBuffer
(Promega) and 3 units of T4 ligase (Promega) with ddH2O added
to a total volume of 10 mL. The solution was incubated at room
temperature for 30 minutes and transformed into DH5a cells.
Positive clones were analyzed by purifying the vector, using
WizardH Plus SV Minipreps DNA Purification System (Promega)
according to manufactures instruction, analyzing linearized vector
on a 0.5% agarose gel for 90 minutes at 70 V. Finally the insertion
of correct insert into the vector was confirmed by sequencing.
Virus Generation and Infection. HEK293T cells (70–80%
confluent, Genehunter) cultured in 6 well plates were transfected
with 0.625 mg/well pMD2.G (Addgene) 1.25 mg/well psPAX2
(Addgene) and 1 mg/well pSicoR PGK puro constructs, either
containing the LGALS1 oligo or the Non-targeting/scrambled
oligo by using the FuGENE 6 (Roche) method according to
manufacturers instruction. The supernatants, from 25 cm
2 of
HEK293T cells containing virus particles, were collected 24 and
48 h after transfection, filtered with a 0.45 mm filter, diluted 1:1
with the culture medium, and added to hMSC-BD11 cells in a
25 cm
2 flask supplemented with 6 g/mL Polybrene for infection.
Twenty-four hours after a second round of infection, 3 g/mL
puromycin was added for selection until all control cells were
killed. The puromycin resistant cells were expanded and
maintained in medium supplemented with 0.2 g/mL puromycin.
An estimated 500.000 cells initially survived the selection to make
the BD11-shLGALS1 and BD11-shControl pooled populations
expanded and used for tumorigenicity studies within four passages
of adenoviral vector transduction.
Xenograft tumorigenicity
Immunodeficient mice (NOD/LtSz-Prkdcscid) were maintained
in pathogen-free conditions. Cells (5610
6) below passage 5 were
mixed with Matrigel 1:1 before implantation (100 mL) to facilitate
establishment and transplanted subcutaneously into the dorsal
surface of 8-week old female NOD/SCID mice. After 14 days
tumours were harvested and perpendicular diameters measured
for an estimation of tumour volume. Tissue samples were fixed in
4% formaldehyde-0.075 mol/L NaPO4 (pH 7), dehydrated,
embedded in paraffin and sectioned at 4 mm for histological and
immunohistochemical evalulation.
Immunohistochemistry of lentivirus transfected -BD11
cell tumours
For histological analysis, deparaffinised 4 mm thick sections
were immunohistochemically stained with immunoperoxidase
detection and Envision Plus according to manufacturer’s instruc-
tions (Dako, Glostrup, Denmark). Murine specific anti-CD34
antibody and human specific anti-CD99 antibody were used as
described above. Human specific anti-galectin-1 antibody clone
25C1 (Novocastra, Leica Biosystems, Newcastle, UK) was used at
1:100 dilution. Haematoxylin and Eosin Y (Bie & Berntsens
Reagenslaboratorium) was used as counterstain, photomicro-
graphs were captured under bright field illumination with an
inverted microscope DM4500 B equipped with Leica DFC300 FX
Digital Color Camera (Leica Microsystems A/S, Herlev, Den-
mark).
Ethics Statement
All animal work was conducted according to institutional guide-
lines and approved by the Danish Animal Experiment Inspector-
ate license number 2002/561-495. Mice were housed in an
environmentally controlled sterile facility, exposed to a 12 hour
light/dark cycle and provided with autoclaved food and water ad
libitum.
Statistical Analyses
A two-tailed t-test was applied to analyze gene expression data.
A p-value of ,0.05 was used as a threshold for statistical
significance. Chalkley count data concerning microvascular den-
sity was statistically compared using Mann-Whitney and Kruskall-
Wallis tests. The statistical software R r2.12.1 (http://www.
R-project.org) was used to determine Ripley’s K function for
endothelial cell distribution on decellularized matrix.
Supporting Information
Movie S1 Time-lapse phase contrast photomicrography of the
cord-morphogenesis induced within 72 hours by serum depriva-
tion (at 0 hours) in a monolayer of hMSC-TERT20-BD11 cells.
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